Industry Verticals »

All Categories

Insights »

About TMR »

Anxiety Disorders and Depression Treatment Market

Anxiety Disorders and Depression Treatment Market [Drug Classes: SSRIs, SNRIs, Benzodiazepines, Beta Blockers, TCAs, TeCAs, Atypical Antipsychotics, Anticonvulsants and MAOIs] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Global Anxiety Disorders and Depression Treatment Market: Snapshot

The global anxiety disorders and depression treatment market is expected to witness a slight downfall in the next few years. The rising number of patent expiry is one of the major factors that is projected to hamper the growth of the overall on the next few years. However, with the rising awareness among consumers and the rapid development of the healthcare segment, especially in the emerging economies are predicted to enhance the growth of the overall market in the next few years. In addition to this, the advent of new technologies and treatments is predicted to offer potential growth opportunities for the market players, which is expected to support the growth of the global anxiety disorders and depression treatment market in the next few years.

As per the market research study by Transparency Market Research, in 2013, the global market for anxiety disorders and depression treatment was worth US$22.5 bn and is predicted to go down to US$18.2 bn by the end of 2020. The market is predicted to register a 1.25% CAGR between 2014 and 2020.

Increasing Adoption of Generic Drugs to Enhance Market Growth in Coming Years

The global market for anxiety disorders and depression treatment has been classified on the basis of drug class into tricyclic antidepressants (TCAs), atypical antipsychotics, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), benzodiazepines, tetracyclic antidepressants (TeCA), anticonvulsants and beta blockers. Among these, the serotonin-norepinephrine reuptake inhibitors segment is projected to lead the global market with a large share in the next few years. Furthermore, the selective serotonin reuptake inhibitors segment is likely to witness a promising growth rate in the near future, owing to the rising adoption of generic drugs.

Furthermore, on the basis of pipeline, the global market for anxiety disorders and depression treatment has been classified into ALKS-5461, Brexpiprazole (OPC-34712), and Brintellix (Vortioxetine - Lu AA21004).

Rising Prevalence of Psychiatric Disorders to Drive Asia Pacific Market

Among the key regional segments, North America is projected to account for a large share of the global market in the next few years. The strong growth of this region can be attributed to the presence of a large number of patients who are suffering from different types of anxiety disorders and depression. In addition to this, the rising awareness among patients regarding the availability of enhanced drugs and treatments is predicted to enhance the growth of the North America market in the coming few years. On the other hand, Asia Pacific is projected to observe a healthy growth in the coming few years, thanks to the rising prevalence of psychiatric disorders. Moreover, the rapid growth of the economy in the nations, such as Japan, China, and Australia is projected to enhance the growth of the market in the next few years.

The global market for anxiety disorders and depression treatment is extremely fragmented in nature with a presence of a large number of players and a high level of competition among the key players. The key players in the market are emphasizing on the development of new products, which is predicted to enhance the growth of the market in the near future. In addition to this, the rising mergers and acquisitions and strategic collaborations are projected to offer potential growth opportunities for the market players in the next few years. Some of the key players operating in the anxiety disorders and depression treatment market across the globe are Eli Lilly and Company, AstraZeneca plc, Forest Laboratories, Inc., H. Lundbeck A/S, GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., Merck & Co., Inc., and Sanofi S.A.

    1. Introduction

        1.1. Report Description

        1.2. Market Segmentation

        1.3. Research Methodology

        1.4. Assumptions

    2. Executive Summary

        2.1. Market Snapshot: Global Anxiety Disorders and Depression Treatment Market

        2.2. Comparative Analysis: Global Anxiety Disorders and Depression Treatment Market, By Geography, 2013 and 2020 (Value %)

    3. Global Anxiety Disorders and Depression Treatment Market Overview

        3.1. Market Dynamics and Overview

        3.2. Market Drivers

            3.2.1. Rising geriatric population expected to boost market growth

            3.2.2. Greater efficacy and reduced side effects of drugs in various classes likely to drive market growth

            3.2.3. Escalating prevalence of depression and anxiety disorders likely to contribute to market growth

        3.3. Market Restraints

            3.3.1. Patent expirations of major drugs during the forecast period expected to impede market growth

            3.3.2. Dry pipeline of novel drugs is hindering market growth

            3.3.3. Drug resistant-mental disorders likely to challenge augmentation of the market

            3.3.4. Increasing number of generic drug variants might negatively affect market growth

        3.4. Market Opportunities

            3.4.1. Improving distribution network in budding economies

            3.4.2. Development of herbal remedies

        3.5. Porter’s Five Forces Analysis

            3.5.1. Bargaining Power of Suppliers

            3.5.2. Bargaining Power of Buyers

            3.5.3. Threat of Substitutes

            3.5.4. Threat of New Entrants

            3.5.5. Competitive Rivalry

        3.6. Event Impact Analysis

        3.7. Market Attractiveness Analysis: Global Anxiety Disorder and Depression Treatment Market, by Geography

        3.8. Regulatory Framework

        3.9. Market Share Analysis: Global Anxiety Disorders and Depression Treatment Market, by Key Players, 2013 (Value %)

    4. Global Anxiety Disorders and Depression Treatment Market, by Drug Class

        4.1. Overview

            4.1.1. Global Anxiety Disorder and Depression Treatment Market Revenue, by Condition, 2012-2020 (USD Million)

            4.1.2. Global Anxiety Disorders Treatment Market Revenue, by Drug Class, 2012-2020 (USD Million)

            4.1.3. Global Depression Treatment Market Revenue, by Drug Class, 2012-2020 (USD Million)

        4.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

            4.2.1. Global SSRIs Market Revenue, by Anxiety Disorders, 2012-2020 (USD Million)

            4.2.2. Global SSRIs Market Revenue, by Depression, 2012-2020 (USD Million)

        4.3. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

            4.3.1. Global SNRIs Market Revenue, by Anxiety Disorders, 2012-2020 (USD Million)

            4.3.2. Global SNRIs Market Revenue, by Depression, 2012-2020 (USD Million)

        4.4. Atypical Antipsychotics

            4.4.1. Global Atypical Antipsychotics Market Revenue, by Anxiety Disorders, 2012-2020 (USD Million)

            4.4.2. Global Atypical Antipsychotics Market Revenue, by Depression, 2012-2020 (USD Million)

        4.5. Tricyclic Antidepressants (TCAs)

            4.5.1. Global TCAs Market Revenue, by Anxiety Disorders, 2012-2020 (USD Million)

            4.5.2. Global TCAs Market Revenue, by Depression, 2012-2020 (USD Million)

        4.6. Tetracyclic Antidepressants (TeCAs)

            4.6.1. Global TeCAs Market Revenue, by Anxiety Disorders, 2012-2020 (USD Million)

            4.6.2. Global TeCAs Market Revenue, by Depression, 2012-2020 (USD Million)

        4.7. Monoamine Oxidase inhibitors (MAOIs)

            4.7.1. Global MAOIs Market Revenue, by Anxiety Disorders, 2012-2020 (USD Million)

                4.7.1.1. Global MAOIs Market Revenue, by Depression, 2012-2020 (USD Million)

        4.8. Benzodiazepines

            4.8.1. Global Benzodiazepines Market Revenue, by Anxiety Disorders, 2012-2020 (USD Million)

            4.8.2. Global Benzodiazepines Market Revenue, by Depression, 2012-2020 (USD Million)

        4.9. Beta-Blockers

            4.9.1. Global Beta-Blockers Market Revenue, by Anxiety Disorders, 2012-2020 (USD Million)

        4.10. Anticonvulsants

            4.10.1. Global Anticonvulsants Market Revenue, by Anxiety Disorders, 2012-2020 (USD Million)

    5. Global Anxiety Disorders and Depression Treatment Market, Pipeline Analysis

        5.1. Overview

        5.2. Brintellix (Vortioxetine - Lu AA21004)

            5.2.1. Global Brintellix Market Revenue, 2014-2020 (USD Million)

        5.3. Brexpiprazole (OPC-34712)

            5.3.1. Global Brexipiprazole Market Revenue, 2016-2020 (USD Million)

        5.4. ALKS-5461

            5.4.1. Global ALKS-5461 Market Revenue, 2016-2020 (USD Million)

    6. Global Anxiety Disorders and Depression Treatment Market, by Geography

        6.1. Overview

            6.1.1. Global Anxiety Disorders and Depression Treatment Market Revenue, by Geography, 2012-2020 (USD Million)

            6.1.2. Global Anxiety Disorders Treatment Market Revenue, by Geography, 2012-2020 (USD Million)

        6.2. North America

            6.2.1. North America Anxiety Disorders and Depression Treatment Market Revenue, 2012-2020 (USD Million)

        6.3. Europe

            6.3.1. Europe Anxiety Disorders and Depression Treatment Market Revenue, 2012-2020 (USD Million)

        6.4. Asia Pacific

            6.4.1. Asia Pacific Anxiety Disorders and Depression Treatment Market Revenue, 2012-2020 (USD Million)

        6.5. Rest of the World (RoW)

            6.5.1. RoW Anxiety Disorders and Depression Treatment Market Revenue, 2012-2020 (USD Million)

    7. Recommendations

        7.1. Emphasis on Developing Novel and Combination Products

        7.2. Targeting Emerging Economies (China, Singapore, Brazil, Dubai, India, South Africa and Mexico) for Marketing Generic Pharmaceuticals

        7.3. Strategic Partnership with Biopharmaceutical Organizations

    8. Company Profiles

        8.1. AstraZeneca PLC

            8.1.1. Company Overview

            8.1.2. Financial Overview

            8.1.3. Product Portfolio

            8.1.4. Business Strategies

            8.1.5. Recent Developments

        8.2. Eli Lilly and Company

            8.2.1. Company Overview

            8.2.2. Financial Overview

            8.2.3. Product Portfolio

            8.2.4. Business Strategies

            8.2.5. Recent Developments

        8.3. Forest Laboratories, Inc.

            8.3.1. Company Overview

            8.3.2. Financial Overview

            8.3.3. Product Portfolio

            8.3.4. Business Strategies

            8.3.5. Recent Developments

        8.4. GlaxoSmithKline plc

            8.4.1. Company Overview

            8.4.2. Financial Overview

            8.4.3. Product Portfolio

            8.4.4. Business Strategies

            8.4.5. Recent Developments

        8.5. H. Lundbeck A/S

            8.5.1. Company Overview

            8.5.2. Financial Overview

            8.5.3. Product Portfolio

            8.5.4. Business Strategies

            8.5.5. Recent Developments

        8.6. Johnson & Johnson

            8.6.1. Company Overview

            8.6.2. Financial Overview

            8.6.3. Product Portfolio

            8.6.4. Business Strategies

            8.6.5. Recent Developments

        8.7. Merck & Co., Inc.

            8.7.1. Company Overview

            8.7.2. Financial Overview

            8.7.3. Product Portfolio

            8.7.4. Business Strategies

            8.7.5. Recent Developments

        8.8. Pfizer, Inc.

            8.8.1. Company Overview

            8.8.2. Financial Overview

            8.8.3. Product Portfolio

            8.8.4. Business Strategies

            8.8.5. Recent Developments

        8.9. Sanofi-Aventis

            8.9.1. Company Overview

            8.9.2. Financial Overview

            8.9.3. Product Portfolio

            8.9.4. Business Strategies

            8.9.5. Recent Developments

    List of Tables

    TABLE 1: Market Snapshot: Global Anxiety Disorders and Depression Treatment Market

    TABLE 2: Global Anxiety Disorder and Depression Treatment Market Revenue, by Condition, 2012-2020 (USD Million)

    TABLE 3: Global Anxiety Disorders Treatment Market Revenue, by Drug Class, 2012-2020 (USD Million)

    TABLE 4: Global Depression Treatment Market Revenue, by Drug Class, 2012-2020 (USD Million)

    TABLE 5: Global Anxiety Disorders and Depression Treatment Market Revenue, by Geography, 2012-2020 (USD Million)

    TABLE 6: Global Anxiety Disorders Treatment Market Revenue, by Condition, 2012-2020 (USD Million)

    List of Figures

    FIG. 1: Anxiety Disorders and Depression Treatment: Market Segmentation

    FIG. 2: Global Depression Treatment Market, by Drug Class, 2013 (USD Million)

    FIG. 3: Global Anxiety Disorders Treatment Market, by Drug Class, 2013 (USD Million)

    FIG. 4: Global Anxiety Disorders and Depression Treatment Pipeline Drugs Market (USD Million)

    FIG. 5: Comparative Analysis: Global Anxiety Disorders and Depression Treatment Market, by Geography, 2013 and 2020 (Value %)

    FIG. 6: Anxiety Disorders and Depression Treatment Market, Drivers, and Restraints

    FIG. 7: Porter’s Five Forces Analysis: Anxiety Disorders and Depression Treatment Market

    FIG. 8: Market Attractiveness Analysis: Global Anxiety Disorder and Depression Treatment Market, by Geography

    FIG. 9: Major Developments in Anxiety Disorders and Depression Treatment Market

    FIG. 10: Market Share Analysis: Global Anxiety Disorders and Depression Treatment Market, by Key Players, 2013 (Value %)

    FIG. 11: Global SSRIs Market Revenue, By Anxiety Disorders, 2012 – 2020 (USD Million)

    FIG. 12: Global SSRIs Market Revenue, By Depression, 2012 – 2020 (USD Million)

    FIG. 13: Global SNRIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)

    FIG. 14: Global SNRIs Market Revenue, by Depression, 2012 – 2020 (USD Million)

    FIG. 15: Global Atypical Antipsychotics Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)

    FIG. 16: Global Atypical Antipsychotics Market Revenue, by Depression, 2012 – 2020 (USD Million)

    FIG. 17: Global TCAs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)

    FIG. 18: Global TCAs Market Revenue, by Depression, 2012 – 2020 (USD Million)

    FIG. 19: Global TeCAs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)

    FIG. 20: Global TeCAs Market Revenue, by Depression, 2012 – 2020 (USD Million)

    FIG. 21: Global MAOIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)

    FIG. 22: Global MAOIs Market Revenue, by Depression, 2012 – 2020 (USD Million)

    FIG. 23: Global Benzodiazepines Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)

    FIG. 24: Global Benzodiazepines Market Revenue, by Depression, 2012 – 2020 (USD Million)

    FIG. 25: Global Beta-Blockers Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)

    FIG. 26: Global Anticonvulsants Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)

    FIG. 27: Global Brintellix Market Revenue, 2014 – 2020 (USD Million)

    FIG. 28: Global Brexipiprazole Market Revenue, 2016 – 2020 (USD Million)

    FIG. 29: Global ALKS-5461 Market Revenue, 2016 – 2020 (USD Million)

    FIG. 30: North America Anxiety Disorders and Depression Treatment Market Revenue, 2012-2020 (USD Million)

    FIG. 31: Europe Anxiety Disorders and Depression Treatment Market Revenue, 2012-2020 (USD Million)

    FIG. 32: Asia Pacific Anxiety Disorders and Depression Treatment Market Revenue, 2012-2020 (USD Million)

    FIG. 33: RoW Anxiety Disorders and Depression Treatment Market Revenue, 2012-2020 (USD Million)

    FIG. 34: AstraZeneca plc: Annual Revenue 2011-2013 (USD Million)

    FIG. 35: Eli Lilly and Company: Annual Revenue, 2011-2013 (USD Million)

    FIG. 36: Forest Laboratories, Inc.: Annual Revenue, 2011-2013 (USD Million)

    FIG. 37: GlaxoSmithKline plc: Annual Revenue, 2011-2013 (USD Million)

    FIG. 38: H. Lundbeck A/S: Annual Revenue, 2011-2013 (USD Million)

    FIG. 39: Johnson & Johnson: Annual Revenue, 2011-2013 (USD Million)

    FIG. 40: Merck & Co., Inc.: Annual Revenue, 2011-2013 (USD Million)

    FIG. 41: Pfizer, Inc.: Annual Revenue: 2011-2013 (USD Million)

    FIG. 42: Sanofi: Annual Revenue, 2011-2013 (USD Million)

Copyright © Transparency Market Research, Inc. All Rights reserved

Anxiety Disorders and Depression Treatment Market

Schedule a Call